Durvalumab with or without tremelimumab after liver radiation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed liver cancer (hepatocellular carcinoma) from biopsy or a scan that meets liver-disease criteria
- You have at least one measurable tumor spot that has not had radiation or other local treatment yet
- A doctor recommends radiation for you (for pain or to reduce risk of blockage or other complications)
- Your liver function is in an allowed range (Child-Pugh A, or B7/B8 if other measures are okay)
- Your body is strong enough for treatment (limited organ lab results and good enough kidney function)
- You can safely receive immune medicines (no contraindications) and you can follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
This trial tests a combination of three drugs—durvalumab, tremelimumab, and zanzalintinib—along with Y-90 radioembolization (a procedure that delivers radiation directly to liver tumors) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.